Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1830

Sort by

Sort Order Select

Journal Articles

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting

Noam E. Kopmar, MD, Megan Othus, PhD, Kelda Gardner, PA-C, Carole M. Shaw, BA, Anna B. Halpern, MD, Bart L. Scott, MD, Paul C. Hendrie, MD PhD, Roland B. Walter, MDPhDMS, Pamela S. Becker, MD PhD, Elihu H. Estey, MD, Mary-Elizabeth M. Percival, MD

Blood (2019) 134 (Supplement_1): 2214.

https://doi.org/10.1182/blood-2019-123315

Published: 2019

Journal Articles

A Thrombotic Biomarker-Based Risk Assessment Scoring Model for Disease Recurrence in Breast Cancer Patient Candidate to Systemic Chemotherapy

Blood (2019) 134 (Supplement_1): 2426.

https://doi.org/10.1182/blood-2019-129820

Published: 2019

Journal Articles

Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma

Patrizia Mondello, MD PhD MSc, Angelo Fama, MD, Melissa C Larson, Zhi-Zhang Yang, MD, Jose C Villasboas, Andrew L. Feldman, MD, Susan L Slager, PhD, Brian K. Link, MD, Sergei Syrbu, MD PhD, Anne J Novak, PhD, Thomas M. Habermann, MD, Thomas E. Witzig, MD, Grzegorz Nowakowski, MD, James R. Cerhan, MD PhD, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 121.

https://doi.org/10.1182/blood-2019-126233

Published: 2019

Journal Articles

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

Sarah Gillessen, MD, Annette Plütschow, Michael Fuchs, MD, Jana Markova, MD, Richard Greil, MD, Max S. Topp, MD, Julia Meissner, MD, Josée M Zijlstra, MD PhD, Dennis A. Eichenauer, Volker Diehl, MD, Peter Borchmann, MD PhD, Andreas Engert, MD, Bastian von Tresckow, MD

Blood (2019) 134 (Supplement_1): 129.

https://doi.org/10.1182/blood-2019-125249

Published: 2019

Journal Articles

Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes

Blood (2019) 134 (Supplement_1): 506.

https://doi.org/10.1182/blood-2019-123974

Published: 2019

Journal Articles

Overall Survival in Patients with JAK2 and ASXL1 Positive Myeloproliferative Neoplasms

Murtadha Al-Khabori, MD, Shoaib Al-Zadjali, PhD, Iman Al Noumani, Khalil Al Farsi, Salam Al-Kindi, MD, Mohamed Al Huneini, MD, Naglaa Fawaz, MBBChir, MMSc, PhD, Al Lamki Sulayma, MD, Mahdiya Pir Al Bulushi, MD FRCPC, Khalid Al Hashmi, MD, Muna Al Tarshi, MD, Muhanna Almusalhi

Blood (2019) 134 (Supplement_1): 5383.

https://doi.org/10.1182/blood-2019-128309

Published: 2019

Journal Articles

Predictors of Outcomes in Adult Patients with Therapy Related Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - Twenty Year Experience from a Tertiary Care Centre

RAM V Nampoothiri, Arjun Law, MD, Wilson Lam, MD, Zeyad Al-Shaibani, David Loach, MD, Carol Chen, Dennis Dong Hwan Kim, MD PhD, Fotios V. Michelis, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Jeffrey H. Lipton, MD PhD, Auro Viswabandya, MD

Blood (2019) 134 (Supplement_1): 5737.

https://doi.org/10.1182/blood-2019-128445

Published: 2019

Journal Articles

Analysis of Falls in Older Adults with Multiple Myeloma Undergoing First-Line Therapy

Kelly L. Schoenbeck, MD, Tanya M. Wildes, MD, Mark A. Fiala, BS

Blood (2019) 134 (Supplement_1): 5886.

https://doi.org/10.1182/blood-2019-129611

Published: 2019

Journal Articles

Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma

Namrata Singh, MD, Sarah L Mott, Ashley Noel McCarthy, MPH, Sergei Syrbu, MD PhD, Thomas M. Habermann, MD, Andrew L. Feldman, MD, Susan L Slager, PhD, Grzegorz Nowakowski, MD, Thomas E. Witzig, MD, Umar Farooq, MD, James R. Cerhan, MD PhD, Zuhair Ballas, Brian K. Link, MD

Blood (2019) 134 (Supplement_1): 1604.

https://doi.org/10.1182/blood-2019-122737

Published: 2019

Journal Articles

Meta-Analyses of Clinical Trials Comparing the Progression Free Survival and Adverse Events in Treated Versus Observed Patients with Smoldering and Indolent Multiple Myeloma

Fahrettin Covut, MD, Tariq Zuheir Kewan, MD, Apoorva Anandan, MD, Folashade Otegbeye, MBBChir,MPH, James Driscoll, MD PhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 2196.

https://doi.org/10.1182/blood-2019-125954

Published: 2019

Journal Articles

Serum Albumin Level, but Not Nutritional Risk Index Predicts Outcomes in Acute Leukemia Patients after Allo-HSCT

Mikhail Yu. Drokov, MD PhD, Natalia N. Popova, MD, Vera A. Vasilyeva, MD PhD, Ekaterina D. Mikhaltsova, MD PhD, Olga M. Koroleva, MD, Zoya V. Konova, Anna A. Dmitrova, MD, Olga S. Starikova, MD, Ulyana V. Maslikova, MD, Maria V. Dovydenko, MD PhD, Ekterina Usikova, Larisa A. Kuzmina, MD PhD, Elena N. Parovichnikova, MD PhD, Valery G. Savchenko, MD PhD academician

Blood (2019) 134 (Supplement_1): 1987.

https://doi.org/10.1182/blood-2019-126822

Published: 2019

Journal Articles

RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation

Onyee Chan, MD, Chetasi Talati, MD, Hannah H Asghari, MD, Jinming Song, MD PhD, Mohammad Hussaini, MD, Andrew T Kuykendall, MD, David A Sallman, MD, Eric Padron, MD, Rami S. Komrokji, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Asmita Mishra, MD, Kendra L. Sweet, MD

Blood (2019) 134 (Supplement_1): 2052.

https://doi.org/10.1182/blood-2019-129742

Published: 2019

Journal Articles

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

Blood (2019) 134 (Supplement_1): 3891.

https://doi.org/10.1182/blood-2019-127187

Published: 2019

Journal Articles

Elevated Serum Soluble Interleukin-2 Receptor Level Is a Useful Prognostic Factor for Disease-Specific Overall Survival in Patients with Newly Diagnosed Follicular Lymphoma before Initiation of Treatment

Blood (2019) 134 (Supplement_1): 3985.

https://doi.org/10.1182/blood-2019-126399

Published: 2019

Journal Articles

Ibrutinib at First Relapse for Mantle Cell Lymphoma: A United Kingdom Real World Analysis of Outcomes in 169 Patients

Blood (2019) 134 (Supplement_1): 3993.

https://doi.org/10.1182/blood-2019-125947

Published: 2019

Journal Articles

Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients

Abby Statler, PhDMPH, Brian P. Hobbs, PhD, Tomas Radivoyevitch, PhD, Caitlin Siebenaller, PharmD, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Aaron T. Gerds, MD MS, Aziz Nazha, MD, Bhumika J. Patel, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 3836.

https://doi.org/10.1182/blood-2019-128853

Published: 2019

Journal Articles

Treatment of Elderly Patients with Acute Promyelocytic Leukemia: A Real Life Experience of the "Rete Ematologica Lombarda"

Valentina Mancini, MD, Erika Borlenghi, MD, Livia Leuzzi, MD, Claudia Basilico, MD, Massimo Bernardi, MD, Patrizia Zappasodi, MD, Monica Fumagalli, MD, Elisabetta Todisco, MD PhD, Chiara Cattaneo, MD, Federico Lussana, MD, Giambattista Bertani, MD, Erika Ravelli, MD, Nicola Fracchiolla, Mauro Turrini, Giuseppe Rossi, Silvia Cantoni, Roberto Cairoli, MD

Blood (2019) 134 (Supplement_1): 3862.

https://doi.org/10.1182/blood-2019-130089

Published: 2019

Journal Articles

The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI)

Blood (2019) 134 (Supplement_1): 3815.

https://doi.org/10.1182/blood-2019-129396

Published: 2019

Journal Articles

Should a Bulky Mediastinal Mass ≥7cm in the Longest Dimension be Considered an Adverse Prognostic Factor in Patients with Advanced Hodgkin Lymphoma and Negative Interim PET/CT?

Eldad J Dann, MD, Rebeca Lopez-Alonso, Shunan Qi, Tania Mashiach, Michal Weiler-Sagie, Joachim Yahalom, MD

Blood (2019) 134 (Supplement_1): 4051.

https://doi.org/10.1182/blood-2019-122824

Published: 2019

Journal Articles

Dose Reduction or Omission of Vinca Alkaloids during Initial Chemotherapy Treatment Does Not Impact Outcomes in Patients with Lymphoma

Neelam Mistry, MD, Diana Abbott, PhD, Japera Walker Wilkison, MA, Ajay Major, MDMBA, Brad M. Haverkos, MDMPH,MS, Manali Kamdar, MD

Blood (2019) 134 (Supplement_1): 4126.

https://doi.org/10.1182/blood-2019-129208

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting

A Thrombotic Biomarker-Based Risk Assessment Scoring Model for Disease Recurrence in Breast Cancer Patient Candidate to Systemic Chemotherapy

Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes

Overall Survival in Patients with JAK2 and ASXL1 Positive Myeloproliferative Neoplasms

Predictors of Outcomes in Adult Patients with Therapy Related Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - Twenty Year Experience from a Tertiary Care Centre

Analysis of Falls in Older Adults with Multiple Myeloma Undergoing First-Line Therapy

Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma

Meta-Analyses of Clinical Trials Comparing the Progression Free Survival and Adverse Events in Treated Versus Observed Patients with Smoldering and Indolent Multiple Myeloma

Serum Albumin Level, but Not Nutritional Risk Index Predicts Outcomes in Acute Leukemia Patients after Allo-HSCT

RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

Elevated Serum Soluble Interleukin-2 Receptor Level Is a Useful Prognostic Factor for Disease-Specific Overall Survival in Patients with Newly Diagnosed Follicular Lymphoma before Initiation of Treatment

Ibrutinib at First Relapse for Mantle Cell Lymphoma: A United Kingdom Real World Analysis of Outcomes in 169 Patients

Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients

Treatment of Elderly Patients with Acute Promyelocytic Leukemia: A Real Life Experience of the "Rete Ematologica Lombarda"

The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI)

Should a Bulky Mediastinal Mass ≥7cm in the Longest Dimension be Considered an Adverse Prognostic Factor in Patients with Advanced Hodgkin Lymphoma and Negative Interim PET/CT?

Dose Reduction or Omission of Vinca Alkaloids during Initial Chemotherapy Treatment Does Not Impact Outcomes in Patients with Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only